Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true True only under certain conditions Certainty of evidence: low provisional C-CHM-08

Cancer treatment causes 'financial toxicity' even for insured patients, leading some to skip medication.

In short: Financial toxicity from cancer treatment is real and common, especially where patients pay out of pocket; evidence that insured patients skip medication comes mainly from small US studies.
Conclusion: Financial toxicity is real in the US; transferability is limited.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

No Arabic original wording available.

Translation

Cancer treatment causes 'financial toxicity' even for insured patients, leading some to skip medication.

Origin

Source status
Archive editors
Attribution
Archive bibliography (study listed without interpretation)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Population concerned

Insured US cancer patients

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Financial burden of cancer treatment.

2. What is demonstrably correct?

42% of insured US patients seeking copay aid reported significant/catastrophic burden; 20-24% skipped or under-filled prescriptions (A-CHM-19).

3. What is wrong or exaggerated?

The data are US-specific and from a selected population; they are not evidence that treatment itself is harmful.

4. What remains unclear?

Situation in Egypt and Germany.

5. Which studies support it?

A-CHM-19.

6. Which studies contradict it?

None identified; the finding comes from a single US pilot survey in a selected sample (A-CHM-19), and no contradicting study was reviewed.

7. What applies to Germany and Europe?

Statutory health insurance in Germany limits out-of-pocket costs (not quantified here).

8. What is known about Egypt?

Out-of-pocket costs in Egypt not reviewed.

9. What practical conclusion is appropriate?

Ask about social and financial support services.

Assessment details

Rationale for certainty of evidence

Single US pilot survey in a selected sample; plausible and consistent with wider literature (not reviewed).

Regional transferability

Low.

Regional scope of the claim
depends on production conditions
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

True only under certain conditions – The claim holds only for certain doses, groups of people, preparations or circumstances.

Research question: Does cancer treatment cause financial toxicity, including among insured patients, leading some to skip medication?

Research question in detail (PECO)
Population
Patients with cancer
Intervention or exposure
Cancer treatment costs
Comparison
Not applicable
Geographic scope
health-system dependent
Outcomes
  • Catastrophic health expenditure
  • Cost-related non-adherence

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

No high-quality evidence against the claim was found.

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Financial toxicity is common worldwide and worse without insurance; cost-related non-adherence is documented in US data.

Why some studies weigh more

Global meta-analysis for prevalence; US pilot for non-adherence.

Is a causal relationship established? Not applicable Descriptive burden.

Remaining uncertainty

Egypt-specific data (none found in the searches).

Justified conclusion

Mostly true; the specific 'insured patients skip medication' evidence remains limited to small US data.

Does this depend on the country?
General biological effects
Not biological; depends on health-system financing.
Eating habits
Not relevant.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Coverage rules differ between countries (Egyptian coverage not reviewed).
Actual monitoring data
No Egyptian financial-toxicity study found in the searches.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • CI plausibility – 56.1% (48.3-63.8) symmetric; plausible recalculated
  • CI plausibility – Pooled prevalence 56.96% with 95% CI 30.51-106.32: upper bound above 100% is impossible for a proportion; study not used not recalculable from the published data
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Prevalence of financial toxicity
Starting level
high (randomised trials)
Reasons for downgrading
  • inconsistency (definitions)
  • indirectness (insured/non-adherence part)
Result
low

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:"financial toxicity" AND (TITLE:"meta-analysis" OR TITLE:"systematic review") AND (TITLE:"prevalence" OR TITLE:"global" OR TITLE:"worldwide") AND PUB_YEAR:[2019 TO 2026]both directions7
Europe PMC26 October 2026(TITLE:"financial toxicity" OR TITLE:"financial burden" OR TITLE:"catastrophic") AND (TITLE:"cancer") AND (Egypt OR Egyptian OR TITLE:"Arab" OR TITLE:"Middle East" OR TITLE:"low- and middle-income")both directions10

Open questions

Financial toxicity in Egypt.

How deeply was this checked?

2 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 2 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (low)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (low)
    Global meta-analysis supports the burden; the specific insured/non-adherence part remains supported only by small US data, so certainty stays low.
    New sources: I-CHM-116

In plain language

Cancer treatment can be expensive. In a US survey of insured patients, many reported heavy financial strain and some skipped medicines. This depends strongly on the health system.

Studies on this claim

Studies supporting the claim (2)

  • Cancer treatment costs strain even insured US patients

    Zafar SY et al.. Oncologist 2013 · PMID 23442307 · DOI 10.1634/theoncologist.2012-0279
    Cross-sectional studycited by the Tayebat archiveabstract checked

    42% reported a heavy financial burden and many skipped medicines to save money.

    Financial toxicity

    Does the study support the specific claim? Yes · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Describe financial toxicity.

    How was the study done?

    Survey.

    How many people, animals or samples were studied?

    254.

    What was actually found?

    High burden.

    How large was the observed effect?

    42% significant burden.

    What do the results mean in everyday life?

    Ask about financial support services.

    What are the study's limitations?

    Selected sample.

    What does it say about Elawady's specific claim?

    Supports.

    Do the results apply to Germany and Europe?

    Low.

    What can explicitly not be concluded from this study?

    Situation in Germany/Egypt.

    Scientific details →

  • Cancer costs push many patients into financial hardship

    Kitaw TA et al.. BMJ Glob Health 2025 · PMID 39929536 · DOI 10.1136/bmjgh-2024-017133
    Meta-analysisindependent cross-checkabstract checked

    More than half of cancer patients in the pooled studies faced catastrophic health costs.

    Global pooled prevalence of catastrophic health expenditure 56%.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Estimate global financial hardship from cancer

    How was the study done?

    Meta-analysis of 35 studies

    How many people, animals or samples were studied?

    428,373 patients

    What was actually found?

    56% catastrophic expenditure

    How large was the observed effect?

    56.1% (48.3-63.8)

    What do the results mean in everyday life?

    Cost is a real burden that can lead to skipped care

    What are the study's limitations?

    Varied definitions

    What does it say about Elawady's specific claim?

    Supports the claim

    Do the results apply to Germany and Europe?

    Moderate

    What can explicitly not be concluded from this study?

    Does not mean treatment should be refused

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (0)

No studies in this group.

Regional context

Germany / EU

Statutory health insurance in Germany limits out-of-pocket costs (not quantified here).

Egypt

Out-of-pocket costs in Egypt not reviewed.

What applies in my country?

General scientific assessment

Mostly true Financial toxicity is real in the US; transferability is limited.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.. Zafar SY et al.. Oncologist 2013 · PMID 23442307 · DOI 10.1634/theoncologist.2012-0279
  2. The financial toxicity of cancer: unveiling global burden and risk factors - a systematic review and meta-analysis.. Kitaw TA et al.. BMJ Glob Health 2025 · PMID 39929536 · DOI 10.1136/bmjgh-2024-017133

← Back to overview